English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Risankizumab, an anti‐interleukin‐23 monoclonal antibody, achieved significantly ( P  <   0.001) greater Psoriasis Area and Severity Index ( PASI ) and static Physician Global Assessment ( sPGA ) clear or almost clear (0/1) responses than adalimumab in a phase III trial in patients with moderate‐to‐severe psoriasis. Meta‐analyses of the  PASI  50,  PASI  75,  PASI  90,  PASI  100, and  sPGA 0/1 responses after 16 weeks of treatment from eight (three for risankizumab and five for adalimumab) randomized, placebo‐controlled trials were conducted to estimate the efficacy difference between risankizumab and adalimumab. For PASI 75, PASI 90, PASI 100, and  sPGA 0/1 responses, the estimated effect differences (95% confidence interval) between risankizumab and adalimumab were 15.2% (10.1%, 20.4%), 23.7% (15.7%, 31.2%), 20.8% (13.0%, 28.7%), and 20.1% (13.7%, 26.1%), respectively. These results were consistent with the observed efficacy difference from the head‐to‐head phase III trial, which was not included in the meta‐analyses, providing independent, confirmatory evidence of the superior efficacy of risankizumab compared with adalimumab for treatment of moderate‐to‐severe psoriasis.

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority